Los Angeles Biotechnology Network
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ February 3, 2023 ] This February, Stay “Hy” and Spread the Love with Essential Elements Los Angeles Biotech News
  • [ February 3, 2023 ] Poland’s SatRev Signs On for Future Virgin Orbit Flights Los Angeles Biotech News
  • [ February 3, 2023 ] Maternal Mental Health Organization Shares Postpartum Psychosis Symptom Checklist in Response to Recent Postpartum Psychosis Tragedies Los Angeles Biotech News
  • [ February 3, 2023 ] Postdoctoral Fellow – Computational Biology, Computational Chemistry, Bioinformatics – City of Hope – Duarte, CA Los Angeles Biotech Jobs
  • [ February 3, 2023 ] Research Associate – AdvanBio – Irvine, CA Los Angeles Biotech Jobs
HomeLos Angeles Biotech NewsSTAT Plus: Mirati study results set new response bar for KRAS-blocking lung cancer drugs

STAT Plus: Mirati study results set new response bar for KRAS-blocking lung cancer drugs

October 25, 2020 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on STAT Plus: Mirati study results set new response bar for KRAS-blocking lung cancer drugs
A pill from Mirati Therapeutics designed to block the cancer protein KRAS shrank tumors in 45% of patients with advanced lung cancer, according to new data.

Click to view original post

Previous

USC scientists unlock the evolutionary history of the pituitary gland

Next

UCLA Professor named fellow of the California Academy of Sciences

Follow/Subscribe

POST A JOB
Tweets by LABioNetwork

Copyright © 2021 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered